Spero Therapeutics (SPRO) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Spero Therapeutics (SPRO) over the past year, losing 47.4% versus a loss of 50.2%. Zhengye Biotechnology is the larger company by market cap ($66.3 million vs $64.1 million), about 1.0 times the size, while Spero Therapeutics is growing revenue faster (+39.2% vs -34.8%). Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -60.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRO | ZYBT |
|---|---|---|
| Share price | $1.10 | $1.40 |
| Market cap | $64.06M | $66.35M |
| 1-day change | -2.65% | -6.67% |
| YTD return | -52.79% | +21.74% |
| 1-year return | -50.23% | -47.37% |
| 5-year return | -93.48% | — |
| P/E ratio (TTM) | 7.86 | — |
| EPS (TTM) | $0.14 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $66.80M | $16.64M |
| Revenue growth (YoY) | +39.24% | -34.83% |
| Net income (latest FY) | $8.57M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | 9.45% | -60.60% |
| Net margin | 12.83% | -59.99% |
| 52-week high | $3.08 | $8.01 |
| 52-week low | $1.08 | $0.616 |
| Distance from 52-week high | -64.29% | -82.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +354.55% | — |
| Average volume | 962.41K | 5.64M |
| Shares outstanding | 58.23M | 47.39M |
| Employees | 25 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -60.0 cents for Zhengye Biotechnology.
- Spero Therapeutics grew revenue faster in its latest fiscal year (+39.24% vs -34.83%).
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
SPRO vs ZYBT FAQ
Which is bigger, Spero Therapeutics or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $66.35M compared with $64.06M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, SPRO or ZYBT?
ZYBT returned -47.37% over the past 12 months, compared with -50.23% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Spero Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.